Zydus Pharmaceuticals (USA) Inc recalls
18 notices naming Zydus Pharmaceuticals (USA) Inc as the recalling firm, since December 11, 2024. A notice covers specific products and lots, not every product of the firm.
Hazard and remedy text is quoted from the agency, unedited. The tag names the kind of risk with a word from that text. Every notice links to its official page.
Zydus Pharmaceuticals (USA) Inc: Hydrocortisone Sodium Succinate for Injection
Hazard (FDA): Failed Impurities/Degradation Specifications.
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: Mirabegron Extended-Release Tablets
Hazard (FDA): CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity.
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: Erythromycin Tablets and 1 more
Hazard (FDA): CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: Icosapent Ethyl Capsules
Hazard (FDA): Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: Icosapent Ethyl capsules
Hazard (FDA): Subpotent Drug: Due to oxidation caused by leakage of the contents of the capsules
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: traZODONE Hydrochloride Tablets
Hazard (FDA): Failed Tablet/Capsule Specifications: Product complaint received that some tablets had a dent on the plain side of the tablet surface.
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: Bromocriptine Mesylate Capsules
Hazard (FDA): Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules.
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: clomiPRAMINE Hydrochloride and 2 more
Hazard (FDA): cGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acceptable intake limit.
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: Entecavir Tablets and 1 more
Hazard (FDA): Failed impurity/degradation specifications:Out of Specification result for an individual organic impurity
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: Entecavir Tablets and 1 more
Hazard (FDA): Failed Impurity/Degradation Specifications
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: Chlorpromazine Hydrochloride Tablets and 9 more
Hazard (FDA): CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: Succinylcholine Chloride Injection
Hazard (FDA): Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation impurity.
FDAMedicines
Burn
Zydus Pharmaceuticals (USA) Inc: Icosapent Ethyl Capsules 1 gram
Hazard (FDA): Failed Tablet/Capsule specifications; a product complaint was reported for burnt or melted capsules. This was determined to be a result of oxidation by leakage of capsule contents.
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: Esomeprazole Magnesium for Delayed-Release Oral Suspension and 1 more
Hazard (FDA): Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation product during Related Compounds testing during long term stability.
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: chlorproMAZINE Hydrochloride Tablets
Hazard (FDA): CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: Venlafaxine Tablets
Hazard (FDA): Presence of Foreign Substance: Product complaint received for the presence of foreign material embedded resembling a metal shaving in one tablet.
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: Nelarabine Injection and 1 more
Hazard (FDA): Failed Impurities/Degradation Specifications
FDAMedicines
Zydus Pharmaceuticals (USA) Inc: Esomeprazole Magnesium for Delayed-Release Oral Suspension 40 mg
Hazard (FDA): Labeling: Not Elsewhere Classified - Wrong NDC number
FDAMedicines